BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Press Releases

  TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand

  October 20, 2026

   · 

  1 min read
• Press Releases

  Correction: ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026

  October 20, 2026

   · 

  9 min read
• Press Releases

  bitBiome Achieves Milestones in Joint Development Project with Ajinomoto Co., Inc.

  October 20, 2026

   · 

  2 min read
• Press Releases

  SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

  October 20, 2026

   · 

  9 min read
• Press Releases

  Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York

  October 20, 2026

   · 

  5 min read
• Press Releases

  EssilorLuxottica: Q3 2026 Revenue - Revenue growth at 9.0% in Q3, +7.2% at constant currency

  October 20, 2026

   · 

  2 min read
• Press Releases

  Florida Cancer Specialists & Research Institute Leadership Review of Step Therapy Policies Details Troubling Impacts to Cancer Patients

  October 20, 2026

   · 

  5 min read
• Press Releases

  /C O R R E C T I O N - AVEO Oncology, an LG Chem company/

  October 20, 2026

   · 

  3 min read
• Press Releases

  GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging

  October 20, 2026

   · 

  5 min read
• Press Releases

  Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not Candidates for Curative Surgery or Curative Radiation

  October 20, 2026

   · 

  13 min read